![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 37, 26149-26156, September 10, 1999
§,
,
,
,
, and

From the
Department of Biochemistry, University of
Natal, Private Bag X01, 3209 Scottsville, South Africa, the
¶ Department of Biochemistry and Molecular Genetics, University of
Alabama at Birmingham, Birmingham, Alabama 35294, the
Section of
Microbial Pathogenesis, Boyer Center for Molecular Medicine, Yale
University School of Medicine, New Haven, Connecticut 06536, and the
** Abteilung für Klinische Chemie und Klinische Biochemie in der
Chirurgischen Klinik und Poliklinik, Klinikum Innenstadt,
Ludwig-Maximilians-Universität München, Nußbaumstraße 20, D 80336 München, Germany
| |
ABSTRACT |
|---|
|
|
|---|
Trypanosoma brucei contains a soluble
serine oligopeptidase (OP-Tb) that is released into the host
bloodstream during infection, where it has been postulated to
participate in the pathogenesis of African trypanosomiasis. Here, we
report the identification of a single copy gene encoding the
T. brucei oligopeptidase and a homologue from the related
trypanosomatid pathogen Leishmania major. The enzymes
encoded by these genes belong to an emerging subgroup of the prolyl
oligopeptidase family of serine hydrolases, referred to as
oligopeptidase B. The trypanosomatid oligopeptidases share 70% amino
acid sequence identity with oligopeptidase B from the intracellular
pathogen Trypanosoma cruzi, which has a demonstrated role
in mammalian host cell signaling and invasion. OP-Tb exhibited no
activity toward the prolyl oligopeptidase substrate
H-Gly-Pro-7-amido-4-methylcoumarin. Instead, it had
activity toward substrates of trypsin-like enzymes, particularly those
that have basic amino acids in both P1 and P2
(e.g. benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin
kcat/Km = 529 s In this study, we identify and characterize a new member of the
prolyl oligopeptidase family of serine hydrolases (the "S9" family
in the nomenclature of Barrett and Rawlings (1)). This family includes
endopeptidases, aminoacylpeptidases, and dipeptidyl aminopeptidases
(2). The members of this diverse family share significant amino acid
sequence identity within the catalytic domain, and all have activity
that is restricted to the hydrolysis of peptides, not proteins (2, 3).
Although direct evidence is scarce, proposed roles for these enzymes
include neuropeptide and peptide hormone metabolism (4), generation of
As suggested by the name, the majority of the prolyl oligopeptidases
cleave their substrates after proline residues. Examples of these
enzymes are found in some prokaryotes (10, 11), in yeast (9, 12, 13),
and in higher eukaryotes (14-17). However, in some cases, the term
prolyl oligopeptidase now appears to be an unfortunate misnomer. This
is because a smaller subgroup of this family cleaves substrates on the
carboxyl side of basic residues (18-20), not prolyl residues. This
subfamily is referred to as oligopeptidase B, e.g.
Escherichia coli protease II or oligopeptidase B (EC
3.4.21.83). Until recently, examples of the oligopeptidase B subfamily
were restricted to prokaryotes and had received scant attention.
However, studies (including this report) have now shown that
oligopeptidase B enzymes are also found in trypanosomatids and that
these enzymes may play key roles in disease pathology. In the case of
the human pathogen Trypanosoma cruzi, the oligopeptidase appears to play a central role in host cell invasion (20, 21). Studies
show that oligopeptidase B null mutants of T. cruzi have a
markedly impaired ability to infect mice or cultured mammalian cells
(21). This impairment seems to be mediated by disruption of the
oligopeptidase involvement in trypomastigote-induced intracellular Ca2+ transients that occur during mammalian host cell
invasion (20, 22). The proposed function of the oligopeptidase in
T. cruzi entry is that of a processing enzyme that generates
an active signaling ligand for mammalian host cells (23, 24) through the hydrolysis of a stage-specific precursor (20, 21).
However, as with the larger family of prolyl oligopeptidases, it seems
likely that more than one function may be ascribed to this enzyme. All
life cycle stages of T. cruzi express oligopeptidase B (20),
but not all life cycle stages invade mammalian cells. Furthermore,
trypsin-like enzymes with properties similar to those of the T. cruzi oligopeptidase B have been described in other kinetoplastids, including the pathogenic parasite Leishmania
(Refs. 25 and 26 and this report), and in the African trypanosomes, Trypanosoma brucei, Trypanosoma vivax, and
Trypanosoma congolense (27-29). If these enzymes are
homologues of the T. cruzi oligopeptidase B, this raises
intriguing questions regarding the roles of these enzymes in parasites
with such widely different lifestyles. Thus, one goal of this study was
to confirm or refute the contention that the trypsin-like enzymes found
in African trypanosomes belong to the oligopeptidase B subfamily of
prolyl oligopeptidases.
Oligopeptidase B-like enzymes may be important potential
chemotherapeutic targets (as evidenced by the trypanocidal action of
many OP-Tb1 inhibitors (30)).
Our studies have indicated that the T. brucei oligopeptidase, called OP-Tb, may play an important direct role in the
pathogenesis of African trypanosomiasis. During infection, OP-Tb is
released into the host bloodstream, where it is insensitive to serum
protease inhibitors (28). Hence, it is free to cleave regulatory
peptides predicted to be present in host serum. Indeed, the disturbed
hormonal pulsatility and endocrine rhythms (31), the unusual cleavage
of peptide hormones in the blood of T. brucei-infected rats
(32), the diminished levels of regulatory peptides such as atrial
natriuretic factor (which is a substrate for OP-Tb (28)) (33), and many
of the generalized symptoms of trypanosomiasis (34) all point to the
possible role of oligopeptidase B in the disruption of host hormone
metabolism during trypanosome infection. Here, we report that, on the
basis of gene sequence identity and kinetic analyses, the
oligopeptidase from T. brucei (OP-Tb (28)) is an atypical
serine peptidase belonging to the oligopeptidase B subgroup of the
prolyl oligopeptidase family. Comparison of the deduced amino acid
sequences of the trypanosomatid oligopeptidase B genes, including the
Leishmania major sequence that we also report here,
demonstrates that these enzymes are closely related to the bacterial
oligopeptidase B enzymes in terms of sequence identity and substrate
specificity. Together, the oligopeptidase B enzymes define a new
subgroup of the prolyl oligopeptidase family.
Materials--
Fluorogenic peptide substrates were obtained from
Sigma, Cambridge Research Biochemicals (Cambridge, United Kingdom), or
Enzyme Systems Products (Los Angeles, CA). Peptidyl diazomethyl ketones and chloromethyl ketones were from Bachem (Bubendorf, Switzerland). All
other reagents were from Sigma.
Purification of OP-Tb--
T. brucei brucei (clone
ILTat1.1) were passaged in adult male Harlan Sprague-Dawley rats and
purified from infected blood by a combination of Percoll isopycnic
gradient centrifugation (35) and anion-exchange chromatography on
DEAE-cellulose (36). OP-Tb was purified as described previously (28),
and the concentration of active enzyme was determined using
4-methylumbelliferyl p-guanidobenzoate (37).
Enzyme and Protein Assays--
OP-Tb activity was routinely
determined against 5 µM Cbz-Arg-Arg-AMC at 37 °C in
assay buffer (50 mM Tris-HCl and 10 mM
dithiothreitol (pH 8.0)) (28) in a Hitachi F-2000 spectrofluorometer
( Amino Acid Sequencing--
Endoproteinase Lys-C digests of OP-Tb
were resolved by reverse-phase high pressure liquid chromatography as
detailed previously (39). Amino acid sequencing of the N termini of
selected OP-Tb-derived peptides was performed with an Applied
Biosystems Model 473A gas-phase sequencer following the manufacturer's instructions.
Oligopeptidase B Gene Cloning--
Nitrocellulose filters
spotted with a T. brucei brucei YTat1.1 cosmid library
constructed in a SuperCos vector (provided by Dr. Elisabetta Ullu, Yale
University School of Medicine, New Haven, CT) were screened with a
32P-labeled probe derived from the full-length T. cruzi oligopeptidase B gene generated by polymerase chain reaction
(PCR) as described (20). Positive clones (obtained from Dr. Sara
Melville, T. brucei Genome Project, Cambridge, UK) were
subcloned into pUC19 following EcoRI/PstI
digestion. A subclone containing the entire T. brucei oligopeptidase B gene open reading frame within a 5.0-kilobase EcoRI-PstI insert was sequenced in both
directions (GenBankTM/EBI accession number AF078916). To
obtain the full-length L. major oligopeptidase B gene, an
L. major LV39 sheared DNA cosmid library (40) was screened
in the laboratory of Dr. Angela Cruz (Universidade de São Paulo,
São Paulo, Brazil) using a 32P-labeled full-length
T. cruzi oligopeptidase B gene as a probe. Positive cosmids
provided were subcloned into pUC19 following BamHI
digestion. Sequencing of a positive BamHI subclone revealed that this was a partial clone that lacked an initiation codon. Therefore, sequencing was completed using a positive cosmid clone. 4066 base pairs were sequenced in one direction. Second strand sequencing
was carried out to confirm the L. major oligopeptidase B
gene sequence (GenBankTM/EBI accession number
AF109875).
Generation of Recombinant Oligopeptidase B--
The full-length
T. brucei oligopeptidase B gene was amplified by PCR from
the 5.0-kilobase cosmid subclone using primers (forward, 5'-ACTCGGATCCACTTTCCATCAC-3'; and reverse,
5'-CCTTAGGATCCCAAGTTTCAG-3') with built-in BamHI
sites. PCR was carried out as follows using a Takara LA PCR kit:
94 °C for 2 min; followed by 35 cycles at 94 °C for 1 min,
56 °C for 1 min, and 68 °C for 3 min; and a final 10-min
extension step at 72 °C. The resulting PCR product was cloned into
pCR2.1 (Invitrogen, Madison, WI) and then excised with BamHI
to yield a 2.2-kilobase fragment containing the full-length T. brucei oligopeptidase B gene. This fragment was ligated to the
pET19b expression vector (Novagen, Carlsbad, CA) linearized with
BamHI. A clone containing an insert with the correct
orientation was expressed in E. coli BL21 (Novagen).
Recombinant T. brucei oligopeptidase B was purified on a
Ni2+-agarose column as described previously (20).
Immunoblot Analysis--
Soluble lysates of T. brucei
YTat1.1 procyclics trypomastigotes, T. cruzi tissue culture
trypomastigotes, and L. major promastigotes were prepared in
Dulbecco's phosphate-buffered saline containing 1 mM
MgCl2 and 1 mM CaCl2 as described
(22). 10 µg of soluble parasite lysates or 100 ng of recombinant
peptidase were separated on a Laemmli SDS-polyacrylamide gel under
reducing conditions (42) and blotted onto ImmobilonTM
(Millipore Corp., Bedford, MA). Blots were blocked in antibody dilution
buffer (20 mM Tris-HCl (pH 7.4), 150 mM NaCl,
0.05% (v/v) Tween 20, 5% (w/v) nonfat skim milk, 1% (w/v) bovine
serum albumin, and 0.1% (w/v) sodium azide) overnight at 4 °C prior
to a 1-h incubation at room temperature with 5 µg ml Kinetic Analyses--
Substrate specificity of OP-Tb was
determined using fluorogenic substrates by preincubation of OP-Tb (1.5 ng, 18.75 fmol of active enzyme, 37 °C, 5 min) or recombinant
oligopeptidase (2 ng) in assay buffer, followed by addition of
substrate. The initial steady-state velocity
(v0) was determined by continuous assay for a
range of substrate concentrations (45 nM to 75 µM). Km and
Vmax were determined by hyperbolic regression of
the kinetic data using the software package Hyper Version 1.01 (obtained from Dr. J. S. Easterby, University of Liverpool,
Liverpool, UK). The kcat was determined from
kcat = Vmax/[E]0, where
[E]0 represents the active enzyme concentration.
The pH profile for OP-Tb was conducted as described above, except that
constant ionic strength acetate/Mes/Tris (AMT) buffers (100 mM acetic acid, 200 mM Tris-HCl, 100 mM Mes, 1 mM dithiothreitol, and 4 mM EDTA, I = 0.1) over the pH range 4-12
(43) replaced the assay buffer. Similarly, pH stability of OP-Tb was
investigated by preincubating OP-Tb (15 ng, 188 fmol of active enzyme,
5 min) in the same set of AMT buffers (37 °C, 1 h) before
assaying residual activity of a 10-µl aliquot in AMT buffer at pH 8.
The effect of reducing agents on OP-Tb activity was investigated by
preincubating OP-Tb in assay buffer containing dithiothreitol, GSH, or
L-cysteine (1-25 mM, 37 °C, 5 min) prior to
addition of Cbz-Arg-Arg-AMC (5 µM final concentration).
To test for dimerization of OP-Tb under nonreducing conditions, OP-Tb
was preincubated in 50 mM Tris-HCl (pH 8) in the absence or
presence of dithiothreitol (10 mM) for 5 days at 4 °C.
Samples (25 µl, containing 50 ng of OP-Tb) were subsequently resolved
by molecular exclusion chromatography on a Sephacryl S-200 HR column
(900 × 15 mm, 0.3 ml min Inhibition of OP-Tb--
The mechanism of inhibition of OP-Tb
was determined from the effect of inhibitors on the
Km and Vmax for the
hydrolysis of Cbz-Arg-Arg-AMC. For reversible competitive inhibitors,
the Ki was determined as described (44). The
enzyme-catalyzed hydrolysis of Cbz-Arg-Arg-AMC was monitored
continuously to establish an uninhibited rate of substrate hydrolysis
(v0), after which a 20-fold molar excess of
inhibitor over enzyme was added (in <5% of the total assay volume),
and the new steady-state velocity in the presence of the inhibitor
(vi) was determined. The apparent inhibition
constant in the presence of substrate (Ki(app)) was given by
v0/vi = 1 + [I]/Ki(app). The true
Ki was calculated for competitive inhibitors, catering for the presence of substrate, from the relationship Ki = Ki(app)/1 + [S]/Km, where [S] denotes substrate
concentration. The ka between OP-Tb and reversible
inhibitors was determined as described for irreversible inhibitors,
except that the ka was corrected for the presence of
substrate by multiplying kobs/[I] by 1 + [S]/Km (28). The rate constant for complex
dissociation (kd) was determined from the
relationship Ki = kd/ka (45).
The effects of irreversible serine and cysteine peptidase inhibitors
were investigated as described (46) by adding an aliquot of inhibitor
(10 µl) to a buffered enzyme solution (140 µl, containing 50 ng of
OP-Tb in 50 mM Tris-HCl (pH 8.0), 37 °C) to initiate the
inactivation. Aliquots were removed at timed intervals, and residual
activity (vt) was determined against Cbz-Arg-Arg-AMC as described above. Pseudo first-order inhibition rate constants (kobs) were obtained from plots of ln
vt/v0 versus time, where v0 represents the activity prior to
addition of inhibitor. Apparent second-order inhibition rate constants
(ka) were obtained from the relationship
ka = kobs/[I], where [I]
represents the inhibitor concentration. The time required for the free
enzyme concentration to decrease by 50% (half-life, t1/2) is given by t1/2 = 0.693/ka[I] (44). As thiol-reactive agents may
react with dithiothreitol in solution, ka values
were determined in the presence and absence of dithiothreitol.
Cloning and Sequencing of Oligopeptidase B--
The 80-kDa
oligopeptidase (OP-Tb) was purified from T. brucei as
described previously (28). Amino-terminal sequence analysis of OP-Tb
was unsuccessful, suggesting that the N terminus is blocked. However,
four peptides generated by digestion of OP-Tb with endoproteinase Lys-C
(Fig. 1) were sequenced and revealed 54%
similarity to the deduced amino acid sequences of corresponding
peptides in T. cruzi oligopeptidase B and 30% similarity to
corresponding peptides in the E. coli and Moraxella
lacunata enzymes. This indicated that the T. brucei
peptidase OP-Tb is related to the oligopeptidase B enzymes of the
prolyl oligopeptidase family.
Preliminary Southern blot analysis revealed that the genomes of
T. brucei as well as a related kinetoplastid protozoan
parasite, L. major, contained nucleotide sequences
homologous to the oligopeptidase B gene of T. cruzi (data
not shown). To determine the relationship between OP-Tb and the
putative oligopeptidase B homologues detected by Southern blotting,
cosmid libraries were screened using the T. cruzi
oligopeptidase B gene as a probe. Full-length clones of the
oligopeptidase B genes of T. brucei and L. major
were obtained. The entire intron-free, T. brucei
oligopeptidase B open reading frame was contained within a 5.0-kilobase
EcoRI/PstI fragment subcloned from a positive
cosmid. The gene consisted of 2145 base pairs and is predicted to
encode a polypeptide of 715 amino acids (Fig. 1). The amino acid
sequence of the OP-Tb-derived peptides precisely matched peptide
sequences found in the deduced amino acid sequence of the T. brucei oligopeptidase B gene (Fig. 1), and we therefore conclude
that the T. brucei enzyme (OP-Tb) is encoded by the gene for
oligopeptidase B. Similarly, the full-length gene encoding the L. major oligopeptidase B gene (2196 base pairs) was isolated and
sequenced and encodes a similar protein of 732 amino acids
(GenBankTM/EBI accession number AF109875) (data not shown).
Southern blot analysis using homologous probes revealed that the
oligopeptidase B genes of T. brucei (Fig.
2) and L. major (data not
shown) are present as single copy genes per haploid genome, as
previously shown for the T. cruzi oligopeptidase B gene
(20).
The deduced amino acid sequences of the three trypanosomatid
oligopeptidase B enzymes exhibited significant homology over their
entire sequences. The T. brucei oligopeptidase B is 71% identical to the T. cruzi oligopeptidase and 67% identical
to the L. major oligopeptidase. The overall similarity of
their respective amino acid sequences is 80%. The similarity of the
peptidases was further demonstrated by immunoblot analysis. Polyclonal
antibodies generated against the T. cruzi oligopeptidase B
readily reacted with oligopeptidase B in lysates of T. brucei (Fig. 3, lane 4) and T. cruzi (lane 5; see also Ref. 20). The
full-length T. brucei oligopeptidase B gene was expressed in
E. coli as a catalytically active (Table
I), histidine-tagged recombinant enzyme
(Fig. 3, lane 1) with a yield of ~12 mg/liter of bacterial
culture. Immunoblot analysis demonstrated that it was detected at the
expected size on a Western blot (Fig. 3, lane 2), similar to
the T. cruzi recombinant enzyme (lane 5).
OP-Tb Substrates--
Consistent with the properties of the prolyl
oligopeptidase family (2), our previous findings have demonstrated that
OP-Tb is unable to hydrolyze polypeptide substrates (28), including mammalian plasma proteins.2
Therefore, fluorogenic peptide substrates were employed for the enzymatic characterization of the native and recombinant forms of the
T. brucei oligopeptidase B. The reactions followed
Michaelis-Menten kinetics. The Km values obtained
using the recombinant T. brucei enzyme approximated those
obtained for the purified native enzyme (Table I).
In contrast to the prolyl oligopeptidase class of enzymes, OP-Tb
exhibited no activity against H-Gly-Pro-AMC (Table I).
Instead, peptide hydrolysis by OP-Tb indicated that the enzyme has a
trypsin-like specificity. The presence of basic amino acid residues in
the P1 position (nomenclature of Ref. 49) was obligatory
(see Table I). The poor
kcat/Km for
H-Arg-AMC (0.07 s
A variety of residues were acceptable in the P2 position,
including Arg, Lys, Phe, Leu, Gly, and Pro. Substitution of Arg in
P2 with Lys in Boc-Leu-Arg-Arg-AMC had little (0.01%
increase) effect on kcat/Km,
indicating that Lys and Arg are equally acceptable in P2 in
this situation. However, substitution of Arg in P2 with Lys
in Boc-Gly-Arg-Arg-AMC resulted in a 4-fold decrease in
kcat/Km. Thus, the
substitution of Leu for Gly in P3 had a substantial effect
on the P2 preference for Arg or Lys. A comparison of
Cbz-Arg-Arg-AMC and Cbz-Phe-Arg-AMC hydrolysis indicates that Arg is
preferred over Phe in P2, with a 6.5-fold decrease in
kcat/Km for the
Phe-containing substrate. A comparison of Boc-Val-Gly-Arg-AMC
versus Boc-Val-Pro-Arg-AMC hydrolysis illustrates that
replacing Pro with Gly in P2 is accompanied by a 8.5-fold
increase in kcat/Km. Thus,
the overall P2 preference appears to be Arg/Lys > Gly > Phe > Pro.
OP-Tb Inhibitors--
Both native and recombinant OP-Tb were
inactivated by irreversible inhibitors of serine peptidases (Table
II). The most potent of these inhibitors
was 3,4-dichloroisocoumarin, which had a ka of 142 M
OP-Tb was also inhibited by the peptide aldehydes antipain and
leupeptin, which contain the aldehyde on Arg in P1 (Table
III). The lower Ki and
higher ka of antipain are a likely consequence of
the comparatively basic nature of the antipain tripeptide. No
inhibition was observed for chymostatin, where the aldehyde is present
on Phe in P1. This supports our contention that Phe is not
readily accepted in the P1-binding site (Tables I and III).
Interestingly, OP-Tb was inhibited competitively by E-64
(trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane), with a Ki of 62.5 µM. This contrasts
with the widely held view that E-64 is a class-specific inhibitor of
cysteine peptidases (52), although the inhibition of bovine OP-Tb Effectors--
OP-Tb activity was enhanced by several
reducing agents, including dithiothreitol, glutathione, and cysteine.
Maximal activation (~3-fold) occurred in the presence of 10 mM dithiothreitol (Fig. 4A). This enhancement does not
appear to result from the reduction of catalytically inactive
disulfide-bonded multimers (as has been demonstrated recently for the
thermolysin-like metallo-oligopeptidase (soluble metallo-endopeptidase,
EC 3.4.24.15) (55)). No significant difference was observed in the
elution profiles for two samples of purified OP-Tb fractionated by
molecular exclusion chromatography under reducing and nonreducing
conditions (Fig. 4B). This suggests that no inactive high
molecular mass complexes were formed under our in vitro
experimental conditions.
OP-Tb was maximally stable at neutral pH in the absence of
dithiothreitol (Fig. 5C).
Although OP-Tb had maximal activity at pH 9 (Fig. 5A), it
retained considerable activity (75% of maximal activity) at
physiological pH (pH 7.4). Over the pH range studied, pH exerted a
dramatic effect on the kcat (up to 100-fold),
whereas the Km was relatively unaffected (1.6-fold)
(Fig. 5B). The shape of the curve suggests that OP-Tb
activity is dependent upon residues with pKa values
of ~6 and 10. This is consistent with the ionization of active-site
histidine and serine residues, respectively, of serine peptidases
(56).
The activity of OP-Tb (against Cbz-Arg-Arg-AMC in the presence of 50 µM polyamines) was enhanced by spermine and spermidine (77 and 62%, respectively, over the control values; data not shown). Putrescine and ornithine had no effect. Curiously, heparin, which carries an opposite charge to polyamines, also enhanced OP-Tb activity
(by 58%) at 30 µg ml We have previously reported that bloodstream forms of T. brucei possess a high molecular mass trypsin-like serine peptidase (27) and that this enzyme is released into the blood of T. brucei-infected rats (28). The present studies show that this
trypsin-like enzyme does not belong to the classic class of trypsins,
but instead belongs to the serine peptidases of the prolyl
oligopeptidase subgroup. The classic trypsins and chymotrypsins all
require a free N-terminal amino acid for full expression of enzymatic
activity, and yet, abundant activity can be found in OP-Tb, which has a blocked N terminus, and in recombinant OP-Tb, which has an N-terminal polyhistidine tag. Clearly, a free N terminus is not required by this
enzyme. Additional differences exist. For example, we see no evidence
of a zymogen form (inactive precursor) of OP-Tb. Since each life cycle
stage (29) of T. brucei possesses this cytosolic (28, 57)
enzyme, alternate means of controlling its activity must exist. As
trypanosomes are known to contain the polyamines spermine and
spermidine (58) as well as a number of intracellular reducing agents
such as trypanothione (59), we tested to see if such molecules might
regulate the activity of OP-Tb. The activity of OP-Tb was enhanced by
reducing agents and by spermine and spermidine. Curiously,
dithiothreitol has no enhancing effect on the catalytic activity of the
prolyl oligopeptidase from human brain (60) despite its apparent
similarity to OP-Tb.
The activity of OP-Tb was inhibited by thiol-reactive agents such as
iodoacetate. Because we now know that OP-Tb belongs to the prolyl
oligopeptidase group of enzymes, rather than the classic serine
protease group, such inhibition is now understandable. It is likely
that inhibition by thiol reagents is explained by a crucial cysteine
residue (Cys255 in porcine prolyl oligopeptidase and
perhaps Cys256 in OP-Tb) that is in close proximity to the
catalytic site in the folded enzyme (61). Covalent attachment of bulky
thiol-reactive groups to this cysteine residue is predicted to
interfere, by steric hindrance, with either the substrate binding or
the charge relay system of the catalytic residues.
Prior to the sequencing of the T. brucei and L. major oligopeptidase B genes, the closest homologues of the
T. cruzi enzyme were the oligopeptidase B enzymes from
E. coli and M. lacunata (20). Here, we find that
the trypanosomatid enzymes share ~32% identity with the E. coli and M. lacunata prolyl oligopeptidases, but
exhibit less identity to other "true" post-proline-cleaving enzymes
(in the range of 20%). Since sequence homology among members of the
prolyl oligopeptidase family is greatest within the catalytic domain
(2, 61), this region of the trypanosomatid oligopeptidase B enzymes was
aligned with several prolyl oligopeptidases (Fig. 6). The oligopeptidase B enzymes possess
the GXSXGGZZ consensus sequence (where
X is any residue and Z is a hydrophobic residue) (2) containing the catalytic serine residue (Ser563 in
T. brucei (Fig. 1) and Ser577 in L. major) and exhibit considerable sequence conservation within the
catalytic domain. However, even within this highly conserved region, it
is clear that the oligopeptidase B subfamily of enzymes (T. brucei, T. cruzi, L. major, M. lacunata, and E. coli) exhibit greater homology to each
other than to the post-prolyl-cleaving enzymes (Fig. 6). Furthermore,
the kinetoplastid (T. brucei, T. cruzi, and
L. major) oligopeptidase B enzymes are even more similar to
each other, exhibiting an overall identity of 70%. Since the oligopeptidase B enzymes can be distinguished from the true prolyl oligopeptidases using sequence identity and substrate specificity as
criteria, we propose that the oligopeptidase B enzymes constitute a
subfamily of the prolyl oligopeptidase family defined by Barrett and
Rawlings (2).
1 µM
1). The activity of
OP-Tb was enhanced by reducing agents and by polyamines, suggesting
that these agents may act as in vivo regulators of OP-Tb
activity. This study provides the basis of the characterization of a
novel subgroup of serine oligopeptidases from kinetoplastid protozoa
with potential roles in pathogenesis.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-amyloid protein in Alzheimer's disease (5), memory formation (6), regulation of blood pressure (7), DNA synthesis (8), and processing of
the mating pheromone
-factor (9).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
ex = 370 nm,
em = 460 nm). Protein
assays were conducted according to the modified (38) method of Bradford
(63).
1
polyclonal anti-T. cruzi recombinant oligopeptidase B IgG
(20). Following five 10-min washes in 20 mM Tris-HCl (pH
7.4), 150 mM NaCl, and 0.05% Tween 20, blots were
incubated for 1 h with horseradish peroxidase-conjugated goat
anti-rabbit IgG (Kirkegaard & Perry Laboratories, Inc., Gaithersburg,
MD) diluted to 1:10,000 and developed using the ECL system (Amersham
Pharmacia Biotech).
1, 4 °C) equilibrated in
the preincubation buffer. Column fractions were assayed for activity
against Cbz-Arg-Arg-AMC as described above. Column fractions collected
under nonreducing conditions were reduced prior to assaying by
preincubation with 10 mM dithiothreitol to reactivate
inactive OP-Tb. The effects of divalent metal ions, nucleotides,
polyamines, and heparin were examined by preincubating OP-Tb (5 ng,
62.5 fmol of active concentration, 37 °C, 10 min) in assay buffer
containing these potential effectors, after which residual activity
against 5 µM Cbz-Arg-Arg-AMC was determined. Dithiothreitol was omitted from the assays involving these compounds.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (76K):
[in a new window]
Fig. 1.
Nucleotide and deduced amino acid sequences
of T. brucei oligopeptidase B. The amino acid
sequence is shown immediately below the nucleotide sequence. Both are
numbered on the right. Amino acid sequences obtained by direct
sequencing of OP-Tb peptides generated by endoproteinase Lys-C cleavage
are underlined. The predicted active-site serine residue
(Ser563) appears in a black box. The sequence is
available from GenBankTM/EBI under accession number
AF078916.

View larger version (28K):
[in a new window]
Fig. 2.
Southern blotting to determine the copy
number of the T. brucei oligopeptidase B gene.
T. brucei DNA was digested with no enzyme (lane
1), EcoRI (lane 2), HindIII
(lane 3), PstI (lane 4),
BglII (lane 5), or XhoI (lane
6). Digested DNA was separated on 0.8% agarose gels and
transferred to a nylon membrane. Hybridization was carried out
overnight at 42 °C in 5× SSC, 50% formamide, 5× Denhardt's
solution, and 0.5% (w/v) SDS using the [32P]dCTP-labeled
full-length T. brucei opdB gene as a probe. The blot was
washed to a final stringency of 0.2× SSC at 60 °C and subjected to
autoradiography. kb, kilobases.

View larger version (49K):
[in a new window]
Fig. 3.
Analysis of native oligopeptidase B in
trypanosomatid extracts and purified recombinant oligopeptidase B. 15 µg of recombinant oligopeptidase B (rOP-Tb) were
evaluated for purity on a Coomassie Blue-stained 10%
SDS-polyacrylamide gel (lane 1). 10 µg of soluble extracts
prepared from T. brucei (lane 2) and T. cruzi (lane 3) and 100 ng of recombinant oligopeptidase
B from T. brucei (lane 4) and T. cruzi
(lane 5) were analyzed by immunoblot analysis with
polyclonal anti-T. cruzi oligopeptidase B antibody as
described under "Experimental Procedures."
rOP-Tc, recombinant oligopeptidase B from T. cruzi.
Amidolytic activity of native and recombinant OP-Tb
1
µM
1) and the lack of activity against
H-Gly-AMC and H-Leu-AMC suggest that OP-Tb is not
an aminopeptidase. (This conclusion is also supported by failure of the
aminopeptidase inhibitors amastatin and bestatin to inhibit OP-Tb (see
Table III).) In contrast, the equivalent substrate with its N terminus
blocked with a Cbz group (i.e. Cbz-Arg-AMC) had an elevated
kcat/Km (157-fold). Thus,
substrate binding is more successful when both P1 and
P2 are occupied.
1 s
1, similar to the
ka values for 3,4-dichloroisocoumarin inhibition of
bovine trypsin (198 M
1 s
1) and
human plasmin (133 M
1 s
1) (50).
OP-Tb was also inactivated by 4-(2-aminoethyl)benzenesulfonyl fluoride,
diisopropyl fluorophosphate, and phenylmethanesulfonyl fluoride. The
rates of inactivation by these compounds ranged from 10- to 30-fold
faster than those reported for the inhibition of serum kallikrein
(51).
Irreversible inhibitors of native and recombinant OP-Tb
-trypsin by E-64 by a reversible competitive mechanism with a
Ki of 36 µM has also been reported
(53). Benzamidine, a low molecular mass inhibitor of trypsin-like
peptidases, was a comparatively poor inhibitor of OP-Tb, with a
Ki of 254 µM, compared with
Ki values of 36 µM for bovine
-trypsin and 12 µM for mast cell tryptase (54). This
supports our earlier suggestion that substrate or inhibitor binding is
more effective when two or more substrate-binding sites are occupied
(Table I). The lack of inhibition by EDTA, EGTA, and
1,10-phenanthroline reinforces the idea that OP-Tb has no metal ion
dependence.
Competitive reversible inhibitors of OP-Tb

View larger version (18K):
[in a new window]
Fig. 4.
Effect of reducing agents on OP-Tb
activity. A, OP-Tb (1.5 ng) was assayed in 100 mM Tris-HCl (pH 8) containing dithiothreitol (
), reduced
glutathione (
), or L-cysteine (
) at various
concentrations. Data points represent the means ± S.E.
(n = 3). B, OP-Tb was resolved under
reducing or nonreducing conditions by molecular exclusion
chromatography on a Sephacryl S-200 HR column (900 × 15 mm, 0.3 ml min
1, 4 °C). Column fractions were assayed for
activity against 5 µM Cbz-Arg-Arg-AMC in the presence of
10 mM dithiothreitol. AFU, arbitrary
fluorescence units.

View larger version (17K):
[in a new window]
Fig. 5.
Effect of pH on the activity and stability of
OP-Tb. A, OP-Tb (1.5 ng) was assayed in AMT buffers
(I = 0.1) over the pH range 4.0-12.0 in the presence
of 10 mM dithiothreitol. B, shown are the
individual effects of pH on the Km (
) and
kcat (
) from the data presented in
A. C, OP-Tb (10 ng) was incubated for 1 h at
37 °C in AMT buffers (I = 0.1) over the pH range
4.0-12.0 in the absence (
) and presence (
) of 10 mM
dithiothreitol. Residual enzymatic activity against Cbz-Arg-Arg-AMC was
then determined in AMT buffer at pH 8.
1. Neither ATP nor GTP had any
effect on the activity of OP-Tb, which is consistent with its being
unrelated to the ATP-dependent peptidases.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (72K):
[in a new window]
Fig. 6.
Alignment of the catalytic domains of
oligopeptidase B and prolyl oligopeptidase. Shown are the amino
acid residues composing the predicted catalytic domains of the prolyl
oligopeptidase family based on the structure of the porcine brain
prolyl oligopeptidase (residues 428-710) (61): residues 436-716 of
T. brucei oligopeptidase B (GenBankTM/EBI
accession number AF078916), residues 435-714 of T. cruzi
oligopeptidase B (accession number U69897 (20)), residues 450-731 of
L. major oligopeptidase B (accession number AF109875),
residues 408-682 of M. lacunata oligopeptidase B (accession
number D38405 (19)), residues 407-691 of E. coli
oligopeptidase B (accession number D10976 (18)), residues 414-690 of
Aeromonas hydrophila prolyl oligopeptidase (accession number
730361 (11)), residues 432-705 of Flavobacterium
meningosepticum prolyl oligopeptidase (accession number 130759 (10)), residues 428-710 of human T cells (accession number 1346769 (41)), and porcine brain prolyl oligopeptidases (accession number
130759 (61)). The cleavage specificities of the oligopeptidase B and
post-prolyl-cleaving enzymes are indicated on the right.
The difference in substrate specificity between the prolyl oligopeptidases and the oligopeptidase B enzymes may be explained by comparing the structure and sequence of the prolyl oligopeptidases with the sequences of the oligopeptidase B enzymes (Fig. 6). Several residues in the active-site pocket are predicted to be involved in substrate recognition by the prolyl oligopeptidases (61). Among these residues is a tryptophan (Trp595 in porcine oligopeptidase) that may be involved in stabilizing the interaction with the P1 proline of the substrate (61). Although this tryptophan residue is conserved in the oligopeptidase B enzymes (Trp608 in T. brucei) (Fig. 6), it is surrounded by conserved glutamic acid residues in the oligopeptidase B enzymes, but these are absent in the post-proline-cleaving enzymes. Thus, it seems most likely that these negatively charged residues contribute to the recognition of basic substrates by the oligopeptidase B enzymes.
No information regarding the three-dimensional structure of oligopeptidase B is available, although the structure of porcine prolyl oligopeptidase has been reported recently (61). The active sites of prolyl oligopeptidases were proposed to lie buried in active-site "pits" (2). This suggestion is consistent with the structural observation that access of proteins to the catalytic site of porcine prolyl oligopeptidase is likely to be impeded by the positioning of the catalytic apparatus in a tunnel-like cavity (61). This suggestion is supported by our observations reported here and the previously reported observations of others (48) that oligopeptidase B is unable to hydrolyze proteins and that its activity is not inhibited by high molecular mass peptidase inhibitors.
Although the preponderance of known members of the prolyl
oligopeptidase family are post-proline-cleaving peptidases, our data
indicate that a subgroup of related peptidases is emerging that
exhibits specificity for substrates containing paired basic amino
acids. To date, these oligopeptidase B enzymes have been identified
only in prokaryotes and kinetoplastid protozoan parasites. No
oligopeptidase B enzymes have been identified in or cloned from
mammalian cells. The homologous enzymes from Saccharomyces cerevisiae are specific for cleavage after proline residues (9, 13). The preference of oligopeptidase B for cleavage after paired basic
residues is intriguing since these sites are abundant in precursors of
biologically active molecules and are recognized as sites for
processing (62). It was previously suggested that the oligopeptidase B
enzymes might function as processing enzymes involved in the generation
of biologically active peptides (20, 48). Recently, oligopeptidase B
from T. cruzi was demonstrated to have a role in the
generation of a signaling ligand for mammalian host cells that is
involved in the mechanism of host cell invasion by this intracellular
pathogen (20, 21). Although the physiological function of other
oligopeptidase B enzymes is currently unclear, T. brucei
OP-Tb may play a major role in pathogenesis of disease through the
degradation of regulatory peptide hormones in the blood of infected
hosts in African trypanosomiasis (28). Further structural and
functional characterization of the oligopeptidase B enzymes in
prokaryotes and kinetoplastid protozoan parasites will be useful to
better understand the functions this subgroup of the prolyl
oligopeptidase family carries out in these organisms and may provide
insights into the evolutionary role of this enzyme.
| |
ACKNOWLEDGEMENTS |
|---|
Amino acid sequencing work was carried out (by R. M.) in the laboratory of Dr. F. Lottspeich (Max Planck Institute for Biochemistry, Martinsreid, Germany). Screening of the L. major LV39 cosmid library was carried out in the laboratory of Dr. Angela Cruz. We thank Drs. C. Huynh and P. Kima for critical reading of this manuscript.
| |
FOOTNOTES |
|---|
* This work was supported in part by a National Institutes of Health Grant (to N. W. A.), South African Foundation for Research Development Grant 2034170 and the University of Natal Research Fund (to T. H. T. C.), and German BMBF Bilateral Cooperation Grant 39.6.60B.6.B (to T. H. T. C. and E. A. A.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF078916 and AF109875.
§ Fellow of the South African Foundation for Research Development. Present address: Section of Microbial Pathogenesis, Boyer Center for Molecular Medicine, Yale University School of Medicine, 295 Congress Ave., New Haven, CT 06536-0812.

Performed this work during the tenure of a fellowship award
from the American Heart Association, Connecticut Affiliate, Inc. To
whom correspondence should be addressed: Dept. of Immunology and
Infectious Diseases, Harvard School of Public Health, 665 Huntington
Ave., Boston, MA 02115. Tel.: 617-432-2495; Fax: 617-738-4914; E-mail:
bburleig@hsph.harvard.edu.
2 R. E. Morty, unpublished data.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: OP-Tb, endogenous oligopeptidase B from T. brucei; Cbz, benzyloxycarbonyl; AMC, 7-amino-4-methylcoumarin; PCR, polymerase chain reaction; Mes, 4-morpholineethanesulfonic acid; Boc, t-butoxycarbonyl.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Barrett, A. J., and Rawlings, N. D. (1995) Arch. Biochem. Biophys. 318, 247-250[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Barrett, A. J., and Rawlings, N. D. (1992) Biol. Chem. Hoppe-Seyler 373, 353-360[Medline] [Order article via Infotrieve] |
| 3. | Rawlings, N. D., Polgar, L., and Barrett, A. J. (1991) Biochem. J. 279, 907-911 |
| 4. | Mentlein, R. (1988) FEBS Lett. 234, 251-256[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Shinoda, M., Toide, K., Ohsawa, I., and Kohsaka, S. (1997) Biochem. Biophys. Res. Commun. 235, 641-645[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Toide, K., Shinoda, M., Fujiwara, T., and Iwamoto, Y. (1997) Pharmacol. Biochem. Behav. 56, 427-434[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Welches, W. R., Brosnihan, K. B., and Ferrario, C. M. (1993) Life Sci. 33, 2149-2157 |
| 8. |
Ishino, T.,
Ohtsuki, S.,
Homma, K.,
and Natori, S.
(1998)
J. Biochem. (Tokyo)
123,
540-545 |
| 9. | Julius, D., Blair, L., Brake, A., Sprague, G. F., and Thorner, J. (1983) Cell 32, 839-852[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Yoshimoto, T.,
Kanatani, A.,
Shimoda, T.,
Inaoka, T.,
Kokubo, T.,
and Tsuru, D.
(1991)
J. Biochem. (Tokyo)
110,
873-878 |
| 11. |
Kanatani, A.,
Yoshimoto, T.,
Kitazono, A.,
Kokubo, T.,
and Tsuru, D.
(1993)
J. Biochem. (Tokyo)
113,
790-796 |
| 12. | Fuller, R. S., Sterne, R. E., and Thorner, J. (1988) Annu. Rev. Physiol. 50, 345-362[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Roberts, C.,
Pohlig, G.,
Rothman, J. H.,
and Stevens, T. H.
(1989)
J. Cell Biol.
108,
1363-1373 |
| 14. | Rennex, D., Hemmings, B. A., Hofsteenge, J., and Stone, S. R. (1991) Biochemistry 30, 2195-2203[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Darmoul, D.,
Lacasa, M.,
Baricault, L.,
Marguet, D.,
Sapin, C.,
Trotot, P.,
Barbat, A.,
and Trugnan, G.
(1992)
J. Biol. Chem.
267,
4824-4833 |
| 16. |
Ogata, S.,
Misumi, Y.,
and Ikehara, Y.
(1989)
J. Biol. Chem.
264,
3596-3601 |
| 17. | Vanhoof, G., Goossens, F., Hendriks, L., De Meester, I., Hendriks, D., Vriend, G., Van Broeckhoven, C., and Scharpe, S. (1994) Gene (Amst.) 149, 363-366[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Kanatani, A.,
Masuda, T.,
Shimoda, T.,
Misoka, F.,
Lin, X. S.,
Yoshimoto, T.,
and Tsuru, D.
(1991)
J. Biochem. (Tokyo)
110,
315-320 |
| 19. |
Yoshimoto, T.,
Tabira, J.,
Kabashima, T.,
Inoue, S.,
and Ito, K.
(1995)
J. Biochem. (Tokyo)
117,
654-660 |
| 20. |
Burleigh, B. A.,
Caler, E. V.,
Webster, P.,
and Andrews, N. W.
(1997)
J. Cell Biol.
136,
609-620 |
| 21. | Caler, E. V., Vaena, S., Haynes, P. A., Andrews, N. W., and Burleigh, B. A. (1998) EMBO J. 17, 4975-4986[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Burleigh, B. A.,
and Andrews, N. W.
(1995)
J. Biol. Chem.
270,
5172-5180 |
| 23. |
Rodriguez, A.,
Rioult, M. G.,
Ora, A.,
and Andrews, N. W.
(1995)
J. Cell Biol.
129,
1263-1273 |
| 24. | Leite, M. F., Moyer, M. S., Nathanson, M. H., and Andrews, N. W. (1998) Mol. Biochem. Parasitol. 92, 1-13[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Ashall, F. (1990) Mol. Biochem. Parasitol. 38, 77-87[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Ribeiro de Andrade, A. S., Santoro, M. M., de Melo, M. N., and Mares-Guia, M. (1998) Exp. Parasitol. 89, 153-160[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Kornblatt, J. D., Mpimbaza, G. W. N., and Lonsdale-Eccles, J. D. (1992) Arch. Biochem. Biophys. 293, 25-31[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Troeberg, L., Pike, R. N., Morty, R. E., Berry, R. K., Coetzer, T. H. T., and Lonsdale-Eccles, J. D. (1996) Eur. J. Biochem. 238, 728-736[Medline] [Order article via Infotrieve] |
| 29. | Mbawa, Z., Gumm, I., Fish, W. R., and Lonsdale-Eccles, J. D. (1991) Eur. J. Biochem. 195, 183-190[Medline] [Order article via Infotrieve] |
| 30. | Morty, R. E., Troeberg, L., Pike, R. N., Jones, R., Nickel, P., Lonsdale-Eccles, J. D., and Coetzer, T. H. T. (1998) FEBS Lett. 433, 251-256[CrossRef][Medline] [Order article via Infotrieve] |
| 31. |
Brandenberger, G.,
Buguet, A.,
Spiegel, K.,
Stanghellini, A.,
Muanga, G.,
Bogui, P.,
and Dumas, M.
(1996)
J. Biol. Rhythms
11,
258-267 |
| 32. | Tetaert, D., Soudan, B., Huet-Duvillier, G., Degand, P., and Boersma, A. (1993) Int. J. Pept. Protein Res. 41, 147-152[Medline] [Order article via Infotrieve] |
| 33. | Ndung'u, J. M., Wright, N. G., Jennings, F. W., and Murray, M. (1992) Parasitol. Res. 78, 553-556[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Tizard, I., Nielson, K., Seed, J. R., and Hall, J. E. (1978) Microbiol. Rev. 42, 661-681 |
| 35. | Grab, D. J., and Bwayo, J. J. (1982) Acta Trop. 39, 363-366[Medline] [Order article via Infotrieve] |
| 36. | Lanham, S. M., and Godfrey, D. G. (1970) Exp. Parasitol. 28, 521-534[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Jameson, G. W., Roberts, D. V., Adams, R. W., Kyle, W. S., and Elmore, D. T. (1973) Biochem. J. 131, 107-117[Medline] [Order article via Infotrieve] |
| 38. | Read, S. M., and Northcote, D. H. (1981) Anal. Biochem. 116, 53-64[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Auerswald, E. A., Genenger, G., Mentele, R., Lenzen, S., Assfalg-Machleidt, I., Mitschang, L., Oschkinat, H., and Fritz, H. (1991) Eur. J. Biochem. 200, 131-138[Medline] [Order article via Infotrieve] |
| 40. | Ryan, K., Dasgupta, S., and Beverely, S. M. (1993) Gene (Amst.) 131, 145-150[CrossRef][Medline] [Order article via Infotrieve] |
| 41. |
Shirasawa, Y.,
Osawa, T.,
and Hirashima, A.
(1994)
J. Biochem. (Tokyo)
115,
724-729 |
| 42. | Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve] |
| 43. | Ellis, K. J., and Morrison, J. F. (1982) Methods Enzymol. 87, 405-426[Medline] [Order article via Infotrieve] |
| 44. | Salvesen, G., and Nagase, H. (1989) in Proteolytic Enzymes: A Practical Approach (Benyon, R. J. , and Bond, J. S., eds) , pp. 83-104, IRL Press, Oxford |
| 45. | Beith, J. G. (1995) Methods Enzymol. 248, 59-84[CrossRef][Medline] [Order article via Infotrieve] |
| 46. | Potempa, J., Pike, R. N., and Travis, J. (1997) Biol. Chem. 378, 223-230 |
| 47. | Deleted in proof |
| 48. | Polgàr, L. (1997) Proteins 28, 375-379[CrossRef][Medline] [Order article via Infotrieve] |
| 49. | Schechter, I., and Berger, A. (1967) Biochem. Biophys. Res. Commun. 32, 898-902 |
| 50. | Harper, J. W., Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 1831-1841[CrossRef][Medline] [Order article via Infotrieve] |
| 51. | Markwardt, F., Drawert, J., and Walsmann, P. (1974) Biochem. Pharmacol. 23, 2247-2256[CrossRef][Medline] [Order article via Infotrieve] |
| 52. | Barrett, A. J., Kambhavi, A. A., Brown, M. A., Kirschke, H., Knight, C. G., Tamai, M., and Hanada, K. (1982) Biochem. J. 201, 189-198[Medline] [Order article via Infotrieve] |
| 53. | Sreedharan, S. K., Verma, C., Caves, L. S. D., Brocklehurst, S. M., Gharbia, S. E., Shah, H. N., and Brocklehurst, K. (1996) Biochem. J. 316, 777-786 |
| 54. |
Caughey, G. H.,
Raymond, W. W.,
Bacci, E.,
Lombardy, R. J.,
and Tidwell, R. R.
(1993)
J. Pharmacol. Exp. Ther.
264,
676-682 |
| 55. |
Shrimpton, C. N.,
Glucksman, M. J.,
Lew, R. A.,
Tullai, J. W.,
Marguiles, E. H.,
Roberts, J. L.,
and Smith, A. I.
(1997)
J. Biol. Chem.
272,
17395-17399 |
| 56. | Dunn, B. M. (1989) in Proteolytic Enzymes: A Practical Approach (Benyon, R. J. , and Bond, J. S., eds) , pp. 57-81, IRL Press, Oxford |
| 57. | Lonsdale-Eccles, J. D., and Grab, D. J. (1987) Eur. J. Biochem. 169, 467-475[Medline] [Order article via Infotrieve] |
| 58. | McCann, P. P., Bacchi, C. J., Clarkson, A. B., Seed, J. R., Nathan, H. C., Amole, B. O., Hutner, S. H., and Sjoerdsma, A. (1981) Med. Biol. (Helsinki) 59, 434-440 |
| 59. |
Fairlamb, A. H.,
Blackburn, P.,
Ulrich, P.,
Chait, B. T.,
and Cerami, A.
(1985)
Science
227,
1485-1487 |
| 60. | Kalwant, S., and Porter, A. G. (1991) Biochem. J. 276, 237-244 |
| 61. | Fülöp, V., Böcskei, Z., and Polgár, L. (1998) Cell 94, 161-170[CrossRef][Medline] [Order article via Infotrieve] |
| 62. | Kreil, G. (1990) Trends Biochem. Sci. 15, 23-26[CrossRef][Medline] [Order article via Infotrieve] |
| 63. | Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve] |